• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Eli Lilly

Sunset
Biotech

DNA med-focused biotech Seawolf surfaces with $1.2B Sanofi pact

Gene therapy biotech Seawolf has emerged from the deep with $100 million to fuel its DNA therapeutic ambitions and a billion-dollar deal with Sanofi.
Michael Gibney Nov 16, 2026 5:00am
NVS

AHA: Novartis’ Lp(a) drug shows zero benefit

Nov 7, 2026 9:50am
Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o

Lilly International's Patrik Jonsson to retire—Chutes & Ladders

Oct 30, 2026 8:30am
Lilly

Lilly scraps ph. 2 Alzheimer's program after drug falls short

Oct 29, 2026 2:09pm
Lilly ADA

Lilly’s retatrutide tops Ozempic in ph. 3 diabetes showdown

Oct 28, 2026 7:45am
Eli Lilly Lilly

ESMO: Lilly ADC sees 79% ORR in competitive ovarian cancer space

Oct 24, 2026 2:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings